Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 3/20 | 0.42 |
| ▸ | PDE5A | O76074 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610427 | 1.00 | LATS1 (0.42) | LATS1GBA1PDE5AFLT3ALDH1A1 | |
| SCHEMBL7605601 | 0.86 | FLT3 (0.49) | FLT3 | |
| SCHEMBL7605608 | 0.86 | FLT3 (0.49) | FLT3 | |
| SCHEMBL7610184 | 0.85 | GBA1 (0.50) | LATS1GBA1PDE5AFLT3ALDH1A1 | |
| SCHEMBL7610192 | 0.85 | GBA1 (0.50) | LATS1GBA1PDE5AFLT3ALDH1A1 | |
| SCHEMBL7610909 | 0.85 | FLT3 (0.50) | LATS1FLT3 | |
| SCHEMBL7610903 | 0.85 | FLT3 (0.50) | LATS1FLT3 | |
| SCHEMBL7611242 | 0.83 | GBA1 (0.62) | LATS1GBA1PDE5AALDH1A1LMNA | |
| SCHEMBL7606449 | 0.82 | LATS1 (0.43) | LATS1GBA1FLT3 | |
| SCHEMBL9268502 | 0.82 | LATS1 (0.43) | LATS1GBA1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | LATS1 674/4885GBA1 3263/4885PDE5A 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.